This is the classic website, which will be retired eventually. Please visit the modernized instead.

Key Record Dates Identifier: NCT04956692
Brief Title: Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

First Submitted : July 6, 2021
First Submitted that Met QC Criteria : July 6, 2021
First Posted : July 9, 2021

Last Update Submitted that Met QC Criteria : August 31, 2023
Last Update Posted : September 5, 2023